Indian Rheumatology Association consensus statement on the diagnosis and treatment of axial spondyloarthropathies

Indian Journal of Rheumatology

Volumn 5, Issue 1, 2010, Pages 16-34

  Malaviya, AN ^a   Shankar, S ^b   Arya, V ^c   Dhir, V ^d   Agarwal, V ^e   Pandya, S ^f   Shanmuganandan, K ^b   Chaturvedi, VP ^g   Das, CJ ^d  

^a ISIC Superspeciality Hospital   (India)

^b ARMED FORCES MEDICAL COLLEGE   (India)

^c DR RAM MANOHAR LOHIA HOSPITAL   (India)

^d ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^e SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

^f Nr Samved Hospital Ahmedabad   (India)

^g Army Based Hospital   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; AZATHIOPRINE; BISPHOSPHONIC ACID DERIVATIVE; CYCLOPENTOLATE; CYCLOSPORIN; ETANERCEPT; GLUCOCORTICOID; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; PAMIDRONIC ACID; SALAZOSULFAPYRIDINE; TACROLIMUS; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA;

ANKYLOSIS; ARTHRALGIA; ARTHRITIS; ARTICLE; BACKACHE; BONE EROSION; BONE MARROW; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ACTIVITY; DISEASE DURATION; EDEMA; ENTHESITIS; ERYTHROCYTE SEDIMENTATION RATE; FASCIOTOMY; FATIGUE; FEMALE; HUMAN; INDIA; INHERITANCE; JOINT; LIPID STORAGE; MAJOR CLINICAL STUDY; MALE; MORNING STIFFNESS; MORTALITY; MYALGIA; NUCLEAR MAGNETIC RESONANCE IMAGING; ONSET AGE; OSTEOPOROSIS; PATIENT ASSESSMENT; PHYSIOTHERAPY; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; SACROILIITIS; SCLEROSIS; SCORING SYSTEM; SCREENING; SEX DIFFERENCE; SEX RATIO; SPINE MOBILITY; SPONDYLOARTHROPATHY; SURVIVAL RATE; SYNOVITIS; TOTAL HIP PROSTHESIS; TREATMENT RESPONSE; TUBERCULOSIS; UVEITIS;

EID: 84992258645     PISSN: 09733698     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0973-3698(10)60531-6     Document Type: Article

References (156)

1. Chopra A., Patil J., Billempelly V., Relwani J., and Tandle H.S. WHO-ILAR COPCORD Study. WHO International League of Associations from Rheumatology Community Oriented Program from Control of Rheumatic Diseases. Prevalence of rheumatic diseases in a rural population in western India: a WHO-ILAR COPCORD Study. J Assoc Physicians India 49 (2001) 240-246
2. Mehra N.K., Prakash S., Vaidya M.C., and Malaviya A.N. Ankylosing spondylitis, Reiter's disease and other HLA-B27 related arthropathies in North India. In: Dawkins R.L., Christiansen F.T., and Zilko P.J. (Eds). Immunogenetics in rheumatology (1982), Excerpta Medica, Amsterdam 185-187
3. Brewerton D.A. HLA-B27 and the inheritance of susceptibility to rheumatic diseases. Arthritis Rheum 19 (1976) 656-668
4. Masi A.T. Epidemiology of B27-associated diseases. Ann Rheum Dis 38 Suppl 1 (1979) 131-134
5. Agarwal R., and Malaviya A.N. Clinical characteristics of patients with ankylosing spondylitis in India. Clin Rheumatol 28 (2009) 1199-1205
6. Achuthan K., Porkodi R., Ramakrishnan S., Krishnamurthy V., Madhavan R., Parthiban M., et al. Pattern of rheumatic diseases in south India. V. Ankylosing spondylitis. A clinical and radiological study. J Assoc Physicians India 38 (1990) 774-776
7. Chandrasekaran A.N., Porkodi R., Achuthan K., Madhavan R., and Parthiban M. Spectrum of clinical and immunological features of systemic rheumatic disorders in a referral hospital in south India: primary ankylosing spondylitis. JIRA 2 (1994) 149-152
8. Singh G., Lawrence A., Agarwal V., Misra R., and Aggarwal A. Higher prevalence of extra-articular manifestations in ankylosing spondylitis with peripheral arthritis. J Clin Rheumatol 14 (2008) 264-266
9. Mathew C.M., Bhandarkar P., Siqueira R.D., Borges N.E., and Joshi V.R. Ankylosing spondylitis infemales. Similarities and differences with male spondylitics. J Assoc Physicians India 37 (1989) 334-336
10. Feldtkeller E., Khan M.A., van der Heijde D., van der Linden S., and Braun J. Age at disease onset and diagnosis delay in HLA-B27 negative vs. positive patients with ankylosing spondylitis. Rheumatol Int 23 (2003) 61-66
11. Prakash S., Mehra N.K., Bhargava S., Vaidya M.C., and Malaviya A.N. Ankylosing spondylitis in North India: a clinical and immuno-genetic study. Ann Rheum Dis 43 (1984) 381-385
12. Aggarwal A., Hissaria P., and Misra R. Juvenile ankylosing spondylitis-is it the same disease as adult ankylosing spondylitis?. Rheumatol Int 25 (2005) 94-96
13. Malaviya A.N., and Kotwal P.P. Arthritis associated with tuberculosis. Best Pract Res Clin Rheumatol 17 (2003) 319-343
14. Hermann J., Giessauf H., Schaffler G., Ofner P., and Graninger W. Early spondyloarthritis: usefulness of clinical screening. Rheumatology 48 (2009) 812-816
15. Singh R., Gupta V., and Gupta A. Pattern of uveitis in a referral eye clinic in north India. Ind J Ophthalmol 52 (2004) 121-125
16. Malaviya A.N., Mehra N.K., Adhar G., Jindal K., Bhargawa S., Batta R.K., et al. HLAB27 in patients with seronegative spondarthritides. J Rheumatol 6 (1979) 413-416
17. Khan M.A. HLA-B27 and its subtypes in world populations. Curr Opin Rheumatol 7 (1995) 263-269
18. van der Heijde D., Calin A., Dougados M., et al. Selection of instruments in the core set for DC-ART, SMARD, physical therapy, and clinical record keeping in ankylosing spondylitis. Progress report of the ASAS working group. Assessments in ankylosing spondylitis. J Rheumatol 26 (1999) 951-954
19. Lukas C., Landewe R., Sieper J., Dougados M., Davis J., Braun J., van der Linden S., and van der Heijde D. Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis 68 (2009) 18-246
20. Salaffi F., Stancati A., Silvestri C.A., et al. Minimal clinically important changes in chronic musculoskeletal pain intensity measured on a numerical rating scale. Eur J Pain 8 (2004) 283-291
21. Jones S.D., Koh W.H., Steiner A., et al. Fatigue in ankylosing spondylitis: its prevalence and relationship to disease activity, sleep, and other factors. J Rheumatol 23 (1996) 487-490
22. Dernis-Labous E., Messow M., and Dougados M. Assessment of fatigue in the management of patients with ankylosing spondylitis. Rheumatology 42 (2003) 1523-1528
23. van der Heijde D., Calin A., Dougados M., Khan M.A., van der Linden S., and Bellamy N. Selection of instruments in the core set for DC-ART, SMARD, physical therapy, and clinical record keeping in ankylosing spondylitis. Progress report of the ASAS Working Group. Assessments in Ankylosing Spondylitis. J Rheumatol 26 (1999) 951-954
24. Viitanen J.V., Heikkila S., Kokko M.L., and Kautiainen H. Clinical assessment of spinal mobility measurements in ankylosing spondylitis: a compact set for follow-up and trials?. Clin Rheumatol 19 (2000) 131-137
25. Jenkinson T.R., Mallorie P.A., Whitelock H.C., et al. Defining spinal mobility in ankylosing spondylitis (AS). The bath AS metrology index. J Rheumatol 21 (1994) 1694-1698
26. Deyo R.A., Diehr P., and Patrick D.L. Reproducibility and responsiveness of health status measures. Statistics and strategies for evaluation. Controlled Clin Trials 12 (1991) 142S-158S
27. Pile K.D., Laurent M.R., Salmond C.E., et al. Clinical assessment of ankylosing spondylitis: a study of observer variation in spinal measurements. Br J Rheumatol 30 (1991) 29-34
28. Haywood K.L., Garratt A.M., Jordan K., et al. Spinal mobility in ankylosing spondylitis: reliability, validity and responsiveness. Rheumatology 43 (2004) 750-757
29. Heikkila S., Viitanen J.V., Kautiainen H., and Kauppi M. Sensitivity to change of mobility tests; effect of short term intensive physiotherapy and exercise on spinal, hip, and shoulder measurements in spondyloarthropathy. J Rheumatol 27 (2000) 1251-1256
30. van der Heijde D.M., 't Hof M.A., van Riel P.L., Theunisse L.A., Lubberts E.W., van Leeuwen M.A., et al. Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Ann Rheum Dis 49 (1990) 916-920
31. Mander M., Simpson J.M., McLellan A., et al. Studies with an enthesis index as a method of clinical assessment in ankylosing spondylitis. Ann Rheum Dis 46 (1987) 197-202
32. Heuft-Dorenbosch L., Spoorenberg A., van Tubergen A., et al. Assessment of enthesitis in ankylosing spondylitis. Ann Rheum Dis 62 (2003) 127-132
33. Braun J., Brandt J., Listing J., et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multi-centre trial. Lancet 359 (2002) 1187-1193
34. Pavy S., Brophy S., and Calin A. Establishment of the minimum clinically important difference for the bath ankylosing spondylitis indices: a prospective study. J Rheumatol 32 (2005) 80-85
35. Calin A., Nakache J.P., Gueguen A., et al. Defining disease activity in ankylosing spondylitis: is a combination of variables (Bath Ankylosing Spondylitis Disease Activity Index) an appropriate instrument?. Rheumatology 38 (1999) 878-882
36. Haywood K.L., Garratt A.M., and Dawes P.T. Patient-assessed health in ankylosing spondylitis: a structured review. Rheumatology 44 (2005) 577-586
37. Cohen J.D., Cunin P., Farrenq V., et al. Estimation of the bath ankylosing spondylitis disease activity index cutoff for perceived symptom relief in patients with spondyloarthropathies. J Rheumatol 33 (2006) 79-81
38. van der Heijde D., Lie E., Kvien T.K., Sieper J., Van den Bosch F., Listing J., Braun J.L., and Landewé R. For the Assessment of Spondylo Arthritis International Society (ASAS) ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis 68 (2009) 1811-1818
39. Creemers M.C.W., Franssen M., van't Hof M.A., et al. Assessment of outcome in ankylosing spondylitis: an extended radiographic scoring system. Ann Rheum Dis 64 (2005) 127-129
40. Wanders A.J., Landewe R.B., Spoorenberg A., et al. What is the most appropriate radiologic scoring method for ankylosing spondylitis? A comparison of the available methods based on the outcome measures in rheumatology clinical trials filter. Arthritis Rheum 50 (2004) 2622-2632
41. van der Heijde D., Landewe R., and the ASASWorking Group. Selection of a method for scoring radiographs for ankylosing spondylitis clinical trials, by the assessment in ankylosing spondylitis working group and OMERACT. J Rheumatol 32 (2005) 2048-2049
42. Calin A., Garrett S., Whitelock H., et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the bath ankylosing spondylitis functional index. J Rheumatol 21 (1994) 2281-2285
43. Dougados M., Gueguen A., Nakache J.P., et al. Evaluation of a functional index for patients with ankylosing spondylitis. J Rheumatol 17 (1990) 1254-1255
44. Daltroy L.H., Larson M.G., Roberts N.W., and Liang M.H. A modification of the health assessment questionnaire for the spondyloarthropathies. J Rheumatol 17 (1990) 946-950
45. Fries J.F., Spitz P., Kraines R.G., and Holman H.R. Measurement of patient outcome in arthritis. Arthritis Rheum 23 (1980) 137-145
46. Spoorenberg A., van der Heijde D., de Klerk E., et al. A comparative study of the usefulness of the bath ankylosing spondylitis functional index and the Dougados functional index in the assessment of ankylosing spondylitis. J Rheumatol 26 (1999) 961-965
47. Doward L.C., Spoorenberg A., Cook S.A., et al. Development of the ASQoL: a quality of life instrument specific to ankylosing spondylitis. Ann Rheum Dis 62 (2003) 20-26
48. Helliwell P.S., Marzo-Ortega H., and Tennant A. Comparison of a disease-specific and a generic instrument for measuring health-related quality of life in ankylosing spondylitis. Arthritis Rheum 46 (2002) 3098
49. Anderson J.J., Baron G., van der Heijde D., Felson D.T., and Dougados M. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 44 (2001) 1876-1886
50. Stone M.A., Inman R.D., Wright J.G., and Maetzel A. Validation exercise of the ankylosing spondylitis assessment study (ASAS) group response criteria in ankylosing spondylitis patients treated with biologics. Arthritis Rheum 51 (2004) 316-320
51. Braun J., Pham T., Sieper J., et al. International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis 62 (2003) 817-824
52. Braun J., Davis J., Dougados M., et al. First update of the International ASAS Consensus Statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis 65 (2006) 316-320
53. Dale K. Radiographic gradings of sacroiliitis in Bechterew's syndrome and allied disorders. Scand J Rheumatol Suppl 32 (1979) 92-97
54. Resnick D., Niwayama G., and Goergen T.G. Comparison of radiographic abnormalities of the sacroiliac joint in degenerative disease and AS. AJR Am J Roentgenol 128 (1977) 189-196
55. Dihlmann W. Current radiodiagnostic concept of AS. Skeletal Radiol 4 (1979) 179-188
56. Fam A.G., Rubenstein J.D., Chin-Sang H., and Leung F. Computed tomography in the diagnosis of early AS. Arthritis Rheum 28 (1985) 930-937
57. Yu W., Feng F., Dion E., Yang H., Jiang M., and Genant H.K. Comparison of radiography, computed tomography and magnetic resonance imaging in the detection of sacroiliitis accompanying AS. Skeletal Radiol 27 (1998) 311-320
58. Geijer M., Gadeholt Göthlin G., and Göthlin J.H. The validity of the New York radiological grading criteria in diagnosing sacroiliitis by computed tomography. Acta Radiol 50 (2009) 664-673
59. Oostveen J., Prevo R., den Boer J., and van de Laar M. Early detection of sacroiliitis on magnetic resonance imaging and subsequent development of sacroiliitis on plain radiography. A prospective, longitudinal study. J Rheumatol 26 (1999) 1953-1958
60. Bollow M., Braun J., Hamm B., Eggens U., Schilling A., König H., et al. Early sacroiliitis in patients with spondyloarthropathy: evaluation with dynamic gadolinium-enhanced MR imaging. Radiology 194 (1995) 529-536
61. Sturzenbecher A., Braun J., Paris S., et al. MR imaging of septic sacroiliitis. Skeletal Radiol 29 (2000) 439-446
62. Rudwaleit M., Jurik A.G., Hermann K.G., Landewé R., van der Heijde D., Baraliakos X., et al. Defining active sacroiliitis on magnetic resonance imaging (MRI) for classification of axial spondyloarthritis: a consensual approach by the ASAS/OMERACT MRI group. Ann Rheum Dis 68 (2009) 1520-1527
63. Maksymowych W.P., Inman R.D., Salonen D., et al. Spondyloarthritis research Consortium of Canada magnetic resonance imaging index for assessment of sacroiliac joint inflammation in AS. Arthritis Rheum 53 (2005) 703-709
64. Bredella M.A., Steinbach L.S., Morgan S., Ward M., and Davis J.C. MRI of the sacroiliac joints in patients with moderate to severe AS. Am J Roentgenol 187 (2006) 1420-1426
65. Maksymowych W.P., Inman R.D., Salonen D., et al. Spondyloarthritis Research Consortium of Canada MRI index for assessment of sacroiliac joint inflammation in AS. Arthritis Rheum 53 (2005) 703-709
66. Baraliakos X., Landewe R., and Braun J. MRI in AS. Future Rheumatol 1 (2006) 423-431
67. Baraliakos X., Hermann K.G., Landewe R., et al. Assessment of acute spinal inflammation in patients with AS by magnetic resonance imaging: a comparison between contrast enhanced T1 and short tau inversion recovery (STIR) sequences. Ann Rheum Dis 64 (2005) 1141-1144
68. McGonagle D., Gibbon W., O'Connor P., et al. Characteristic MRI entheseal changes of knee synovitis in spondyloarthropathy. Arthritis Rheum 41 (1998) 694-700
69. Bozgeyik Z., Ozgocmen S., and Kocakoc E. Role of Diffusion-Weighted MRI in the Detection of Early Active Sacroiliitis. Am J Roentgenol 191 (2008) 980-986
70. Pui M.H., Mitha A., Rae W.I., and Corr P. Diffusion-weighted MRI of spinal infection and malignancy. J Neuroimaging 15 (2005) 164-170
71. Hochberg M.C., Bias W.B., and Arnett Jr. F.C. Family studies in HLA-B27 associated arthritis. Medicine (Baltimore) 57 (1978) 463-475
72. Kanga U., Mehra N.K., Larrea C.L., Lardy N.M., Kumar A., and Feltkamp T.E. Seronegative spondyloarthropathies and HLA-B27 subtyes: a study in Asian Indians. Clin Rheumatol 15 Suppl 1 (1996) 13-18
73. Brown M., and Calin A. Susceptibility to ankylosing spondylitis in twins - the role of genes, HLA and the environment. Arthritis Rheum 40 (1997) 1823-1828
74. Brionez T.F., and Reveille J.D. The contribution of genes outside the major histocompatibility complex to susceptibility to ankylosing spondylitis. Curr Opin Rheumatol 20 (2008) 384-391
75. Wellcome Trust Case Control Consortium, The Australo-Anglo-American Spondylitis Consortium. A genome-wide scan of 14,000 non-synonymous coding SNP in 5,500 individuals. Nat Genet 39 (2007) 1329-1336
76. Miceli-Richard C., Said-Nahal R., and Breban M. Impact of sex on inheritance of ankylosing spondylitis. Lancet 355 (2000) 1097-1098
77. Ward M.M. Predictors of the progression of functional disability in patients with ankylosing spondylitis. J Rheumatol 29 (2002) 1420-1425
78. Ward M.M., Hendrey M.R., Malley J.D., Learch T.J., Davis Jr. J.C., Reveille J.D., and Weisman M.H. Clinical and immunogenetic prognostic factors for radiographic severity in ankylosing spondylitis. Arthritis Care Res 61 (2009) 859-866
79. Aggarwal R., and Malaviya A.N. Clinical characteristics of patients with ankylosing spondylitis in India. Clin Rheumatol 28 (2009) 1199-1205
80. Braunstein E.M., Martel W., and Moidel R. Ankylosing spondylitis in men and women: a clinical and radiographic comparison. Radiology 144 (1982) 91-94
81. Boonen A., Chorus A., Miedema H., et al. Employment, work disability, and work days lost in patients with ankylosing spondylitis: a cross sectional study of Dutch patients. Ann Rheum Dis 60 (2001) 353e8
82. Kchir M.M., Ghannouchi M.M., Hamdi W., Azzouz D., Kochbati S., Saadellaoui K., et al. Impact of the ankylosing spondylitis on the professional activity. Joint Bone Spine 76 (2009) 378-382
83. Khan M.A., Khan M.K., and Kushner I. Survival among patients with ankylosing spondylitis: a life-table analysis. J Rheumatol 8 (1981) 86-90
84. Zochling J., and Braun J. Mortality in ankylosing spondylitis. Clin Exp Rheumatol 26 Suppl. 51 (2008) S80-S84
85. Lehtinen K. Mortality and causes of death in 398 patients admitted to hospital with ankylosing spondylitis. Ann Rheum Dis 52 (1993) 174-176
86. Heeneman S., and Daemen M.J. Cardiovascular risks in spondyloarthritides. Curr Opin Rheumatol 19 (2007) 358-362
87. Dagfinder H, Hagen K. Physiotherapy interventions for ankylosing spondylitis (Cochrane review). Oxford, Cochrane Library, 2001.
88. Hidding A., van der Linden S., Boers M., et al. Is group physical therapy superior to individualized therapy in ankylosing spondylitis? A randomized controlled trial. Arthritis Care Res 6 (1993) 117-125
89. van Tubergen A., Boonen A., Landewé R., et al. Cost-effectiveness of combined spa-exercise therapy in ankylosing spondylitis: A randomized controlled trial. Arthritis Rheum 47 (2002) 459-467
90. Dagfinrud H, Kvien TK, Hagen KB. Physiotherapy interventions for ankylosing spondylitis. Cochrane Database of Systematic Reviews 4. CD002822.pub2.DOI, 2004.
91. Santos H., Brophy S., and Calin A. Exercise in ankylosing spondylitis: how much is optimum?. J Rheumatol 25 (1998) 2156-2160
92. Uhrin Z., Kuzis S., and Ward M.M. Exercise and changes in health status in patients with ankylosing spondylitis. Arch Intern Med 160 (2000) 2969
93. Dougados M., Behier J.M., Jolchine I., Calin A., van Der H.D., Olivieri I., et al. Efficacy of celecoxib, a cyclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis: a six-week controlled study with comparison against placebo and against a conventional nonglucocorticoidal antiinflammatory drug. Arthritis Rheum 44 (2001) 180-185
94. Boulos P., Dougados M., Macleod S.M., and Hunsche E. Pharmacological treatment of ankylosing spondylitis: a systematic review. Drugs 65 (2005) 2111-2127
95. Zochling J., van der Heijde D., Burgos-Vargas R., Collantes E., Davis Jr. J.C., Dijkmans B., et al. ASAS/EULAR recommendations for the management of ankylosing spondylitis. Annals of the Rheumatic Diseases 65 (2006) 442-452
96. Wanders A., van der Heijde D., Landewe R., Behier J.M., Calin A., Olivieri I., et al. Nonglucocorticoidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum 52 (2005) 1756-1765
97. van der Heijde D., Baraf H.S., Ramos-Remus C., Calin A., Weaver A.L., Schiff M., et al. Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: results of a fifty-two-week, randomized, controlled study. Arthritis Rheum 52 (2005) 1205-1215
98. Deeks J.J., Smith L.A., and Bradley M.D. Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials. BMJ 325 (2002) 619-623
99. Sudbø J., Lee J.J., Lippman S.M., et al. Nonglucocorticoidal anti-inflammatory drugs and the risk of oral cancer: A nested case-control study. Lancet 366 (2005) 1359-1366
100. Maugars Y., Mathis C., Vilon P., and Prost A. Corticoglucocorticoid injection of the sacroiliac joint in patients with seronegative spondylarthropathy. Arthritis Rheum 35 (1992) 564-568
101. Luukkainen R., Nissila M., Asikainen E., Sanila M., Lehtinen K., Alanaatu A., et al. Periarticular corticoglucocorticoid treatment of the sacroiliac joint in patients with seronegative spondylarthropathy. Clin Exp Rheumatol 17 (1999) 88-90
102. Mintz G., Enriquez R.D., Mercado U., Robles E.J., Jimenez F.J., and Gutierrez G. Intravenous methylprednisolone pulse therapy in severe ankylosing spondylitis. Arthritis Rheum 24 (1981) 734-736
103. Peters N.D., and Ejstrup L. Intravenous methylprednisolone pulse therapy in ankylosing spondylitis. Scand J Rheumatol 21 (1992) 134-138
104. Evard F., Neumann V., Hopkins R., and Wright V. Pulsed methyl-prednisolone therapy in rheumatoid arthritis. Ann Rheum Dis 50 (1991) 66
105. Nasswetter G., Pineiro D.J., Garcia Morteo O.M., Maldonado Cocco J.A., Barreira J.C., and Vazquez M. Holter monitoring in ankylosing spondylitis patients during methylprednisolone pulse therapy. Clin Rheumatol 3 (1984) 29-31
106. Chen J., and Liu C. Sulfasalazine for ankylosing spondylitis. Cochrane Database Syst Rev (2005) CD004800.
107. Kirwan J., Edwards A., Huitfeldt B., Thompson P., and Currey H. The course of established ankylosing spondylitis and the effects of sulphasalazine over 3 years. Br J Rheumatol 32 (1993) 729-733
108. Lehtinen A., Leirisalo-Repo M., and Taavitsainen M. Persistence of enthesopathic changes in patients with spondyloarthropathy during a 6-month follow-up. Clin Exp Rheumatol 13 (1995) 733-736
109. Benitez-Del-Castillo J.M., Garcia-Sanchez J., Iradier T., and Banares A. Sulfasalazine in the prevention of anterior uveitis associated with ankylosing spondylitis. Eye 14 Pt A (2000) 340-343
110. Altan L., Bingol U., Karakoc Y., Aydiner S., Yurtkuran M., and Yurtkuran M. Clinical investigation of methotrexate in the treatment of ankylosing spondylitis. Scand J Rheumatol 30 (2001) 255-259
111. Roychowdhury B., Bintley-Bagot S., Bulgen D.Y., Thompson R.N., Tunn E.J., and Moots R.J. Is methotrexate effective in ankylosing spondylitis?. Rheumatology (Oxford) 41 (2002) 1330-1332
112. Gonzalez-Lopez L., Garcia-Gonzalez A., Vazquez-Del-Mercado M., Munoz-Valle J.F., and Gamez-Nava J.I. Efficacy of methotrexate in ankylosing spondylitis: a randomized, double blind, placebo controlled trial. J Rheumatol 31 (2004) 1568-1574
113. Maksymowych W.P., Jhangri G.S., Fitzgerald A.A., LeClercq S., Chiu P., Yan A., et al. A six-month randomized, controlled, double-blind, dose-response comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of nonglucocorticoidal antiinflammatory drug-refractory ankylosing spondylitis. Arthritis Rheum 46 (2002) 766-773
114. Grover R., Shankar S., Aneja R., Marwaha V., Gupta R., and Kumar A. Treatment of ankylosing spondylitis with pamidronate: an open label study. Ann Rheum Dis 65 (2006) 688-689
115. Malaviya A.N., Kapoor S., Garg S., Ahmad I., and Raja R.R. A new strategy of drug treatment in NSAID-unresponsive ankylosing spondylitis: combination of pamidronate and methylprednis-olone monthly intravenous infusions on the background of a combination of disease modifying drugs sulfasalazine and methotrexate. J Assoc Physicians India 55 (2007) 193-197
116. Adami S., Bhalla A.K., Dorizzi R., Montesanti F., Rosini S., Salvagno G., et al. The acute-phase response after bisphosphonate administration. Calcif Tiss Int 41 (1987) 326-331
117. Wei J.C., Chan T.W., Lin H., Huang F., and Chou C. Thalidomide for severe refractory ankylosing spondylitis: a 6-month open-label trial. J Rheumatol 30 (2003) 2627-2631
118. Huang F., Gu J., Zhao W., Zhu J., Zhang J., and Yu D. One-year open-label trial of thalidomide in ankylosing spondylitis. Arthritis Care Res 47 (2002) 15
119. Braun J., Brandt J., Listing J., et al. Treatment of active ankylosing spondylitis with infliximab: a randomized controlled multicentre trial. Lancet 359 (2002) 1187-1193
120. van Der Heijde D., Dijkmans B., Geusens P., et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 52 (2005) 582-591
121. van Den Bosch F., Kruithof E., Baeten D., et al. Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy. Arthritis Rheum 46 (2002) 755-765
122. Braun J., Baraliakos X., Brandt J., et al. Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years. Rheumatology (Oxford) 44 (2005) 670-676
123. Davis Jr. J.C., van der Heijde D., Braun J., Dougados M., Cush J., Clegg D.O., et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 48 (2003) 3230-3236
124. Brandt J., Khariouzov A., Listing J., Haibel H., Sorensen H., Grassnickel L., et al. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum 48 (2003) 1667-1675
125. Calin A., Dijkmans B.A., Emery P., Hakala M., Kalden J., Leirisalo-Repo M., et al. Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis 63 (2004) 1594-1600
126. Davis JC, van der Heijde DM, Braun J, et al. Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks. Ann Rheum Dis 2005; in press.
127. Braun J., Pham T., Sieper J., Davis J., van der Linden S., Dougados M., et al. International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis 62 (2003) 817-824
128. Braun J., Davis J., Dougados M., Sieper J., van der Linden S., van der Heijde D., et al. First update of the International ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis 65 (2006) 316-320
129. Keystone E.C. Safety issues related to emerging therapies for rheumatoid arthritis. Clin Exp Rheumatol 22 Suppl 35 (2004) S148-S150
130. In: Hamilton C.D. (Ed). Infectious complications of treatment with biologic agents. Curr Opin Rheumatol 16 (2004) 393-398
131. Kumar A. Experience with anti-tumor necrosis factor-a therapy in India. APLAR J Rheumatol 9 (2006) 136-141
132. Keane J., and Bresnihan B. Tuberculosis reactivation during immunosuppressive therapy in rheumatic diseases: diagnostic and therapeutic strategies. Curr Opin Rheumatol 20 (2008) 443-449
133. Acevedo-Vásquez E., Poncet de León D., and Gambao-Cárdinas R. Latent infection and tuberculosis disease in rheumatoid arthritis. Rheumat Dis Cin N Am 35 (2009) 163-181
134. Winthrop K.L., and Chiller T. Preventing and treating biologic-associated opportunistic infections. Nat Rev Rheumatol 5 (2009) 405-410
135. Handa R., Misra R., Chaturvedi, Pispati P.K., Rao U., Joshi V.R., and for the Indian Rheumatology Association. Guidelines for tuberculosis prophylaxis during anti-tumour necrosis factor-a treatment: Ind Rheumatol Assoc. APLAR J Rheumatol 9 (2006) 181-183
136. British Thoracic Society, and Standards of Care Committee. BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-{alpha} treatment. Thorax 60 (2005) 800-805
137. Malaviya AN, Kapoor S, Garg S, Rawat R. Success of the recommended screening strategy for preventing tuberculosis flare in patients with inflammatory rheumatic diseases (IRD) receiving tumour necrosis factor-a inhibitors (iTNF-a) in India-a follow-up report. J Rheumatol, in Press.
138. Malaviya A.N., Kapoor S., Garg S., Rawat R., Shankar S., Nagpal S., et al. Preventing tuberculosis flare in patients with inflammatory rheumatic diseases receiving tumor necrosis factor-alpha inhibitors in India - An audit report. J Rheumatol 36 (2009) 1414-1420
139. Smieja M.J., Marchetti C.A., Cook D.J., and Smaill F.M. Isoniazid for preventing tuberculosis in non-HIV infected persons. Cochrane Database Syst Rev 2 (2000) CD001363.
140. Gardam M.A., Keystone E.C., Menzies R., et al. Anti-tumour necrosis factor agents and tuberculosis risk. Mechanisms of action and clinical management. Lancet Infect Dis 3 (2003) 148-155
141. Rosenbaum J.T. Acute anterior uveitis and spondyloarthropathies. Rheum Dis Clin North Am 18 (1992) 143
142. Banares A., Hernandez-Garcia C., Fernandez-Gutierrez B., et al. Eye involvement in the spondyloarthropathies. Rheum Dis Clin North Am 24 (1998) 771-778
143. Maillefert J.F., Aho L.S., El Maghraoui A., et al. Changes in bone density in patients with ankylosing spondylitis: a two-year follow-up study. Osteoporos Int 12 (2001) 605-609
144. Munoz-Fernandez S., Hidalgo V., Fernandez-Melon J., et al. Sulfasalazine reduces the number of flares of acute anterior uveitis over a one-year period. J Rheumatol 30 (2003) 1277
145. Lustig M.J., and Cunningham Jr. E.T. Use of immunosuppressive agents in uveitis. Curr Opin Ophthalmol 14 (2003) 399-412
146. Smith J.A., Thompson D.J., Whitcup S.M., et al. A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis. Arthritis Rheum 53 (2005) 18
147. Galor A., Perez V.L., Hammel J.P., and Lowder C.Y. Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation. Ophthalmology 113 (2006) 2317
148. Dougados M., Revel M., and Khan M.A. Spondylarthropathy treatment: progress in medical treatment, physical therapy and rehabilitation. Baillieres Clin Rheumatol 12 (1998) 717-736
149. Kane D., Greaney T., Shanahan M., et al. The role of ultrasonography in the diagnosis and management of idiopathic plantar fasciitis. Rheumatology 40 (2001) 1002-1008
150. van der Heijde D., Braun J., McGonagle D., and Siegel J. Treatment trials in ankylosing spondylitis: current and future considerations. Ann Rheum Dis 61 (2002) iii24-iii32
151. Biasi D., Carletto A., Caramaschi P., Pacor M.L., Maleknia T., and Bambara L.M. Efficacy of methotrexate in the treatment of ankylosing spondylitis: a three-year open study. Clin Rheumatol 19 (2000) 114-117
152. Marzo-Ortega H., McGonagle D., O'Connor P., and Emery P. Efficacy of etanercept in the treatment of the entheseal pathology in resistant spondylarthropathy: a clinical and magnetic resonance imaging study. Arthritis Rheum 44 (2001) 2112-2117
153. Calin A., and Elswood J. The outcome of 138 total hip replacements and 12 revisions in ankylosing spondylitis: High success rate after a mean follow-up of 7.5 years. J Rheumatol 16 (1989) 955
154. Sweeney S., Gupta R., Taylor G., and Calin A. Total hip arthroplasty in ankylosing spondylitis: outcome in 340 patients. J Rheumatol 28 (2001) 1862-1866
155. Seegenschmiedt M.H., Makoski H.-B., Micke O., et al. Radiation prophylaxis for heterotopic ossification about the hip joint-a multicenter study. Int J Radiat Oncol Biol Phys 51 (2001) 756
156. Weissman B.N., Aliabadi P., Weinfeld M.S., et al. Prognostic features of atlantoaxial subluxation in rheumatoid arthritis patients. Radiology 144 (1982) 745